Enlivex Therapeutics (ENLV) Status Update summary

Management background and company overview

• Leadership has a strong track record in drug development, including a $590 million exit and successful product approvals with Pfizer and OPKO Health.

• The company focuses on a novel cell therapy platform targeting macrophages for inflammatory diseases, with a unique, cost-effective, off-the-shelf manufacturing process.

• The management and board bring extensive experience in clinical development, business, and regulatory strategy.

Market opportunity and unmet need

• Knee osteoarthritis affects over 32.5 million adults in the U.S. and 300 million globally, with a market size of $7 billion expected to grow to $15 billion by 2030.

• Current treatments are limited to pain relief and steroids, with no effective long-term therapies, leading to surgeries.

• The prevalence of osteoarthritis increases with age, with 40% of those over 60 affected.

Phase II-A study design and results

• The randomized, double-blind, placebo-controlled trial enrolled 134 patients with moderate to severe knee osteoarthritis, with endpoints at 3, 6, and 12 months.

• Primary endpoint was safety; secondary endpoints included pain and function changes at three and six months, using the validated WOMAC questionnaire.

• A responder subgroup (primary idiopathic OA, age 60+) showed a 72% improvement in pain over placebo, with high statistical significance.

• Efficacy increased with age, reaching up to 217% pain reduction over placebo in patients 65+.

• Across all endpoints, including pain, function, and stiffness, results exceeded FDA minimum thresholds for phase III studies.